Earnings ·
MaxCyte raises full-year revenue guidance to $34M, reports Q3 core revenue of $8.1M
MXCTMaxcyte, Inc.
MaxCyte reported preliminary third-quarter 2026 core business revenue of approximately $8.1 million, representing a 26% increase compared to the same period in 2025. The company also recognized more than $1.0 million in Strategic Platform License Program-related revenue, including a $1.0 million milestone payment. Consequently, MaxCyte raised its full-year 2026 revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million. This revised outlook includes core business revenue expected at approximately $28 million and SPL Program-related revenue of approximately $6 million. The company will report final financial results on November 10, 2026. MaxCyte is a cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics.